Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 4 drugs with upcoming expirations
Activity
Last 14 days
A Single Center, Controlled Study to Evaluate the Ability of Sunscreen Products to Modulate the Effects of Deep UVA +/- HEV Blue Light Induced Pigmentation and Biomarkers of Cutaneous Oxidative Stress
A Monocentric and Open-Label Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Research Participants
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Pepcid — FLUXID
Application NDA021712 (NDA)
Advil — CHILDREN'S ELIXSURE
Application NDA021604 (NDA)
Imodium — LOPERAMIDE HYDROCHLORIDE
Application NDA021855 (NDA)
Zyrtec — ZYRTEC ALLERGY
Application NDA019835 (NDA)
Zyrtec — CHILDREN'S ZYRTEC ALLERGY
Application NDA022155 (NDA)
Zyrtec — CETIRIZINE HYDROCHLORIDE ALLERGY
Application NDA022429 (NDA)
Advil — CALDOLOR
Application NDA022348 (NDA)
Tylenol — OFIRMEV
Application NDA022450 (NDA)
Zyrtec — ZYRTEC ALLERGY
Application NDA022578 (NDA)
Advil — ADVIL
Application NDA201803 (NDA)
Tylenol — ACETAMINOPHEN
Application NDA204767 (NDA)
Zyrtec — ZERVIATE
Application NDA208694 (NDA)
Rhofade — RHOFADE
Application NDA208552 (NDA)
Zyrtec — QUZYTTIR
Application NDA211415 (NDA)
Zyrtec — CHILDREN'S ZYRTEC ALLERGY
Application NDA021621 (NDA)
Rhofade — UPNEEQ
Application NDA212520 (NDA)
Tylenol — ACETAMINOPHEN
Application NDA204957 (NDA)
Tylenol — ACETAMINOPHEN
Application NDA206610 (NDA)
Tylenol — ACETAMINOPHEN
Application NDA206968 (NDA)
Pepcid — FAMOTIDINE
Application NDA219935 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)